We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
- Authors
Bennett, Charles L; Silver, Samuel M; Djulbegovic, Benjamin; Samaras, Athena T; Blau, C Anthony; Gleason, Kara J; Barnato, Sara E; Elverman, Kathleen M; Courtney, D Mark; McKoy, June M; Edwards, Beatrice J; Tigue, Cara C; Raisch, Dennis W; Yarnold, Paul R; Dorr, David A; Kuzel, Timothy M; Tallman, Martin S; Trifilio, Steven M; West, Dennis P; Lai, Stephen Y; Henke, Michael
- Abstract
The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin are licensed to treat chemotherapy-associated anemia in patients with nonmyeloid malignancies. Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs.
- Publication
JAMA, 2008, Vol 299, Issue 8, p914
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.299.8.914